Clinical trial Recruiting at 1 site Observational Ages 18 and up

Investigating treatment outcomes for patients with cardiogenic shock

Official title: SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK - an International, Observational Registry

Run by Universitätsklinikum Hamburg-Eppendorf · NCT03313687 · Data updated 2026-11-12

This study looks at how different treatments for cardiogenic shock work for patients to see which ones are most effective and what side effects they might have.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment2500 (estimated)
SponsorUniversitätsklinikum Hamburg-Eppendorf
Academic / other
Locations1 site (Hamburg)
StatusRecruiting
StartedSeptember 1, 2017
Main results expectedDecember 31, 2030
Study endsDecember 31, 2031
Registry record updatedOctober 7, 2021
Trial IDNCT03313687 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are patients diagnosed with cardiogenic shock who are being treated at a tertiary care hospital.

Probably not a fit

Patients under the age of 17 will not benefit from this study as they are excluded from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This international observational registry aims to assess the clinical outcomes of patients experiencing cardiogenic shock. The study focuses on various treatment strategies, including interventional therapies and mechanical circulatory support, while monitoring the drug therapies and devices used in these patients. By documenting the practices at participating sites, the study seeks to provide insights into the effectiveness and side effects of current treatment approaches for cardiogenic shock.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment strategies and outcomes for patients suffering from cardiogenic shock.

How similar studies have gone: Other studies focusing on treatment outcomes in cardiogenic shock have shown promise, indicating that this approach is relevant and potentially beneficial.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with cardiogenic shock treated at a tertiary care hospital.

Exclusion Criteria:

* Age ≤17 years.

Where it's running

  • University Heart Center
    Hamburg, Germany
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.